Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi‐center retrospective case series

Abstract

Children with recalcitrant CSU, even those <12 years old, respond well to standard-dose, third-line omalizumab therapy at rates similar to adults. Yet, some cases may become non-responsive with ongoing treatment.